TCM

Tang Capital Management Portfolio holdings

AUM $1.98B
1-Year Est. Return 21.62%
This Quarter Est. Return
1 Year Est. Return
+21.62%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$1.98B
AUM Growth
+$171M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
220
New
Increased
Reduced
Closed

Top Buys

1
+$28.3M
2
+$26.3M
3
+$22.9M
4
BA icon
Boeing
BA
+$20.9M
5
SYRE icon
Spyre Therapeutics
SYRE
+$17.2M

Top Sells

1
+$37.7M
2
+$29M
3
+$24.3M
4
ONC
BeOne Medicines Ltd
ONC
+$10.1M
5
CRSP icon
CRISPR Therapeutics
CRSP
+$9.07M

Sector Composition

1 Healthcare 94.16%
2 Technology 1.37%
3 Industrials 1.32%
4 Communication Services 1.26%
5 Consumer Discretionary 0.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AFMD
201
DELISTED
Affimed
AFMD
– –
-148,315
ALLK
202
DELISTED
Allakos
ALLK
– –
-8,693,687
ATRA icon
203
Atara Biotherapeutics
ATRA
$113M
– –
-75,196
JBIO
204
Jade Biosciences
JBIO
$460M
– –
-1,993
BLUE
205
DELISTED
bluebird bio
BLUE
– –
-400,000
CAPR icon
206
Capricor Therapeutics
CAPR
$291M
– –
-79,100
CRSP icon
207
CRISPR Therapeutics
CRSP
$6.58B
– –
-266,500
ELEV
208
DELISTED
Elevation Oncology
ELEV
– –
-4,760,000
KRON
209
DELISTED
Kronos Bio
KRON
– –
-1,345,413
LXRX icon
210
Lexicon Pharmaceuticals
LXRX
$552M
– –
-1,150,268
NXTC icon
211
NextCure
NXTC
$29M
– –
-33,679
OTLK icon
212
Outlook Therapeutics
OTLK
$62.6M
– –
-400,000
PHAT icon
213
Phathom Pharmaceuticals
PHAT
$994M
– –
-1,200,000
QNCX icon
214
Quince Therapeutics
QNCX
$99.4M
– –
-184,383
RVPH icon
215
Reviva Pharmaceuticals
RVPH
$50.1M
– –
-510,329
SLRN
216
DELISTED
ACELYRIN
SLRN
– –
-9,818,115
VIR icon
217
Vir Biotechnology
VIR
$871M
– –
-500,000
GRAL
218
GRAIL Inc
GRAL
$3.02B
– –
-11,300
ONC
219
BeOne Medicines Ltd
ONC
$35B
– –
-37,000
ITCI
220
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-220,000
5 6 7 8
9